IP Library Granted Patent US 11,633,384
Granted Patent B2
US 11,633,384 · App. 17/213,678 · Granted Apr 25, 2023

Methods of treating hepatic encephalopathy

Inventor: William Forbes (Raleigh, NC)
Assignee: Salix Pharmaceuticals, Inc.
A61K31/437A61K31/08A61K31/352A61K31/395A61K31/4164A61K31/426A61K31/4439A61K31/606A61K31/7016A61K31/785A61K38/14A61K38/31A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,633,384
App. No.
17/213,678
Granted
Apr 25, 2023
Kind
B2
Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Claims (10)

1. A method of increasing the time to development of spontaneous bacterial peritonitis (SBP) in a hepatic encephalopathy patient, comprising administering to the subject 550 mg of rifaximin to the subject two times per day (BID) daily for a period of about 12 months or longer.

2. The method of claim 1 , further comprising administering lactulose.

3. The method of claim 1 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 1 and 24.

4. The method of claim 1 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level less than or equal to ten.

5. The method of claim 1 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 11 and 18.

6. The method of claim 1 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 19 and 24.

7. The method of claim 1 , wherein the subject has a Conn score of 0 or 1.

8. The method of claim 1 , wherein administration of the rifaximin reduces hospitalization frequency by from between about 13% to about 69%.

9. The method of claim 1 , wherein there is a decrease in blood ammonia concentration from baseline after administration of the rifaximin to the subject.

10. The method of claim 1 , wherein there is an increase in critical flicker frequency values from baseline after administration of the rifaximin to the subject.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2021
From: FORBES, WILLIAM
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 056956/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2021
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 056956/0165 →
SECURITY INTEREST Recorded Jun 21, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 056603/0237 →
SECURITY INTEREST Recorded Jun 21, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056603/0227 →
Continuity (10)
Continuation 16893651 · Jun 5, 2020
Continuation 16414018 · May 16, 2019
Continuation 15922010 · Mar 15, 2018
Continuation 15460704 · Mar 16, 2017
Continuation 14612697 · Feb 3, 2015
Continuation 13768617 · Feb 15, 2013
Continuation 13077373 · Mar 31, 2011
Continuation PCTUS2009059321 · Oct 2, 2009
Provisional Application 61102349 · Oct 2, 2008
Related Publication 20210275507A1 · Sep 9, 2021
Cited By (1)
US 12,697,326